Approximately 5% of non-small cell lung cancers (NSCLC) have anaplastic lymphoma kinase (ALK) rearrangements.[1–4] Patients with ALK-positive NSCLC are more likely to be younger, nonsmokers, and diagnosed with more advanced disease than those with ALK-negative NSCLC.[2,5,6] ALK inhibitors are first-line agents in chemotherapy for ALK-positive lung cancer.[7–10] The treatment of lung cancer has been revolutionized by the advent of immune checkpoint inhibitors (ICIs). This evidence concerns the gene ALK and non-small cell lung carcinoma.